DA 6886

Drug Profile

DA 6886

Alternative Names: 5-HT4 agonist - Dong-A; DA-6886

Latest Information Update: 27 Apr 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Irritable bowel syndrome

Highest Development Phases

  • Phase I Irritable bowel syndrome

Most Recent Events

  • 27 Apr 2016 Phase I development is ongoing in South Korea
  • 31 Dec 2013 Dong-A ST completes a phase I trial in Healthy volunteers in South Korea (NCT01633723)
  • 31 Aug 2012 Phase-I clinical trials in Irritable bowel syndrome (in volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top